Small Cell Lung Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study developed and validated CPH-Lung, a blood test-based model, to improve 6-year lung cancer risk stratification for screening. Utilizing two prospective cohorts of ever-smokers, the model was trained and validated against the PLCOm2012 model. CPH-Lung demonstrated superior discrimination (AUC 0.783 vs. 0.720, p=.0059) and higher sensitivity (e.g., 57.6% vs. 39.2% in women, p<.0001) for detecting lung cancer. This offers a more sensitive tool for identifying high-risk individuals, particularly women and younger patients, potentially enhancing early lung cancer detection in clinical practice.
10.1200/JCO-25-02326
Sep 14 – Sep 21, 2026
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3 randomized trial evaluated tambotatug pelitecan versus topotecan in 451 patients with relapsed extensive-stage small-cell lung cancer after platinum-based therapy. Tambotatug pelitecan significantly improved median overall survival (13.3 vs. 9.4 months; HR 0.46, P<0.001) and progression-free survival (7.4 vs. 2.8 months; HR 0.29, P<0.001), with objective response rates of 59.1% versus 9.7%. Grade 3 or higher adverse events were lower with tambotatug pelitecan (55.4% vs. 77.9%). These findings support tambotatug pelitecan as a more effective and safer second-line option for this aggressive cancer.
10.1056/NEJMoa2610229
Sep 07 – Sep 14, 2026
The changing therapeutic landscape of small-cell lung cancer.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This Series paper summarizes the evolving therapeutic landscape for small-cell lung cancer (SCLC), an exceptionally aggressive malignancy, by reviewing current standards of care, recent biological advances, and emerging novel approaches. Advances in understanding SCLC biology, particularly defining cell-surface proteins, have led to targeted therapies like T-cell engagers, antibody-drug conjugates, radioconjugates, and cell therapies, showing substantial preliminary efficacy. These novel approaches offer new hope for improved management of SCLC, a disease historically refractory to standard treatments after recurrence. The paper highlights promising strategies that could transform clinical practice for this lethal cancer.
10.1016/S0140-6736(26)01244-4
Jul 20 – Jul 27, 2026
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase Ib study evaluated the efficacy and safety of izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in 52 patients with relapsed extensive-stage small cell lung cancer (ES-SCLC). Results demonstrated an overall response rate (ORR) of 48.1% and median overall survival of 12.2 months, with second-line patients achieving a notable 72.7% ORR and 6.2-month median progression-free survival. The treatment showed significant antitumor activity particularly in the second-line setting, though common hematologic toxicities like neutropenia and thrombocytopenia require clinical management. These findings support iza-bren as a promising therapeutic option for aggressive SCLC, prompting an ongoing phase III trial comparing it against standard-of-care topotecan.
10.1200/JCO-26-00243